DiagnosisAid

DiagnosisAid is tackling the critical problem of medical misdiagnosis, which leads to devastating consequences for patients, families, and health systems worldwide. Misdiagnosis affects a staggering 12 million Americans each year, with 40,000-80,000 deaths annually due to diagnostic errors. Globally, the World Health Organization estimates that up to 5% of outpatients in developed countries are improperly diagnosed, while misdiagnosis rates can exceed 10% in lesser developed countries. This translates to over 300 million misdiagnosed cases worldwide per year.

The impact of misdiagnosis is profound and far-reaching. For patients, it can mean delayed or incorrect treatment, prolonged suffering, disability, and even death. Misdiagnosis also erodes trust in the medical system. It exacerbates health disparities, as underserved communities often face the most significant barriers to quality care and bear the brunt of diagnostic errors.

Several key factors contribute to the misdiagnosis crisis:

1. Insufficient data and tools: Physicians often lack access to comprehensive patient data and advanced analytical tools for accurate diagnosis. 

2. Cognitive biases: Doctors may fall prey to mental shortcuts or biases that lead to flawed clinical reasoning.

3. Time pressures: Rushed consultations in overburdened health systems leave little time for thorough diagnostic workups.

4. Fragmented care: Lack of care coordination and data sharing across providers can lead to missed or delayed diagnoses.

5. Lack of diversity: Medical research and training often fail to represent diverse populations, leading to diagnostic blind spots adequately.

DiagnosisAid's quantum AI platform is uniquely designed to address these root causes. By aggregating massive amounts of diverse patient data and generating insights from quantum simulations, our tool empowers physicians with rapid, highly probable differential diagnoses. This helps counter cognitive biases, saves time, and surfaces data-driven insights that may be missed in fragmented care systems. 

We mainly partner with under-resourced health facilities that serve diverse and disadvantaged populations. By democratizing access to cutting-edge diagnostic support, we aim to reduce health disparities and improve outcomes for those most impacted by misdiagnosis.

The scale of the problem demands urgent action. In the US alone, diagnostic errors cost $100 billion annually. Globally, the economic toll is likely in the trillions. However, the actual cost is counted in human lives disrupted and lost. By harnessing the power of quantum computing and AI to revolutionize the diagnostic process, DiagnosisAid ensures that every patient receives the proper diagnosis and care at the right time, regardless of their background or ZIP code. Our solution offers a transformative path to health equity in a world where misdiagnosis is common.

DiagnosisAid is pioneering a transformative solution to the global epidemic of medical misdiagnosis by harnessing the power of quantum computing and artificial intelligence (AI). Our cutting-edge platform leverages these emerging technologies to provide physicians an unparalleled tool for rapid, accurate, and equitable diagnosis.

At the heart of DiagnosisAid is a powerful quantum AI engine that aggregates and analyzes massive amounts of diverse patient data across medical silos. This includes comprehensive health records, symptoms, test results, imaging, treatments, and outcomes from millions of cases worldwide. Our platform identifies complex patterns and correlations that may elude even the most experienced clinicians by applying advanced machine learning algorithms to this vast dataset.

What sets DiagnosisAid apart is our groundbreaking use of quantum computing to generate hyper-realistic patient simulations. These quantum-powered simulations allow us to model countless potential disease trajectories and treatment responses, generating a wealth of predictive insights to inform diagnostic decision-making. Combining real-world data with quantum simulations gives a holistic view of each patient's health landscape.

When a physician inputs a patient's information into DiagnosisAid, our quantum AI algorithm rapidly processes this data against our extensive knowledge base and quantum simulations. Within seconds, the platform generates a ranked list of the most probable diagnoses, along with recommended tests, treatments, and personalized care plans. This empowers doctors to make faster, more accurate diagnostic decisions, reducing the risk of misdiagnosis and ensuring timely, targeted interventions.

Our user-friendly interface is designed for seamless integration into existing clinical workflows. Physicians can access DiagnosisAid securely from any device, inputting patient data through voice commands, text, or structured fields. The platform's intuitive data visualizations and evidence-based recommendations support clinical reasoning without overwhelming users with irrelevant information.

We are forging partnerships with under-resourced health facilities and community health workers in diverse settings to ensure equitable access. By providing subsidized or free access to DiagnosisAid in these contexts, we aim to democratize the benefits of quantum AI-assisted diagnosis, reducing health disparities and improving outcomes for marginalized populations.

As our platform is deployed and refined, it will continuously learn and adapt, incorporating real-world feedback to optimize its diagnostic accuracy and decision support. DiagnosisAid will grow more intelligent and precise with each new case, evolving into an indispensable ally for physicians worldwide.

Imagine a world where every doctor, from the bustling urban hospital to the remote village clinic, has the power of quantum AI at their fingertips. In a world where misdiagnosis is a rarity, every patient receives the proper care at the right time. That is the future DiagnosisAid is building – a future where cutting-edge technology and human compassion combine to transform the landscape of healthcare equity. We are ushering in a new era of diagnostic precision and patient-centered care through quantum computing and AI, one diagnosis at a time.

DiagnosisAid's transformative quantum AI platform is designed to serve a diverse global population, focusing on underserved communities facing healthcare inequities. Our solution directly impacts the lives of patients, families, and healthcare providers across a broad spectrum of settings, from urban safety-net hospitals to rural clinics in developing nations.

The patients we aim to serve often face the most significant barriers to accessing quality healthcare. They include low-income individuals and families, racial and ethnic minorities, indigenous communities, refugees and migrants, people with disabilities, and those living in remote or resource-limited areas. These populations are disproportionately affected by medical misdiagnosis, as they often lack access to comprehensive health services, face language, and cultural barriers, and are underrepresented in medical training.

For these underserved patients, the consequences of misdiagnosis can be devastating. Delayed or incorrect treatment can lead to prolonged suffering, disability, financial hardship, and even death. Misdiagnosis also erodes trust in the healthcare system, leading many to forgo seeking care altogether. This perpetuates a vicious cycle of health disparities and worsens outcomes for already marginalized communities.

DiagnosisAid directly addresses these inequities by democratizing access to cutting-edge diagnostic support. Our platform empowers healthcare providers in underserved settings with the same quantum of AI-powered insights and decision-support tools typically only available in well-resourced institutions. By partnering with community health centers, safety-net hospitals, and global health organizations, we are putting the power of rapid, accurate diagnosis in the hands of those who need it most.

For a patient in a remote village clinic, this could mean the difference between a correct diagnosis of early-stage breast cancer and a missed opportunity for lifesaving treatment. For a refugee family navigating an unfamiliar healthcare system, DiagnosisAid could help a busy emergency room doctor quickly identify a rare genetic disorder, enabling targeted interventions and support services. For an elderly patient with multiple chronic conditions, our platform could untangle the complex interplay of symptoms and medications, optimizing treatment plans and preventing harmful drug interactions.

Beyond individual patients, DiagnosisAid's impact ripples outward to families, communities, and entire health systems. By reducing misdiagnosis and improving outcomes, our solution can help alleviate the emotional and financial toll of prolonged illness and disability on families. Community health indicators can improve as more patients receive timely, appropriate care, fostering greater resilience and productivity. DiagnosisAid can help optimize resource allocation at the health system level, reducing waste and inefficiencies while freeing providers to focus on patient care.

Ultimately, our vision is to create a world where patients receive the highest quality diagnostic care regardless of their background or circumstances. We can improve individual lives and catalyze broader systemic change by harnessing the power of quantum computing and AI to serve the most vulnerable. Through DiagnosisAid, we are working to dismantle the barriers to healthcare equity, one accurate diagnosis at a time. By empowering providers and patients with the tools they need to make informed, evidence-based decisions, we are paving the way for a future where good health is not a privilege but a fundamental human right.


At DiagnosisAid, we are driven by a deep commitment to health equity and a belief in the transformative power of technology to improve lives. Our diverse and passionate team is uniquely positioned to deliver our quantum AI-powered diagnostic solution to underserved communities worldwide, guided by a shared vision of a future where no patient falls through the cracks of misdiagnosis.

Our journey began with a personal tragedy that hit close to home. When our co-founder, Richard Hill, lost his mother to a preventable misdiagnosis, it ignited a fierce determination to tackle this pervasive problem at its roots. Richard has witnessed firsthand the devastating impact of diagnostic errors on marginalized populations. His deep understanding of the systemic barriers to quality care informs every aspect of DiagnosisAid's mission and strategy. Richard is an experienced investment banker (with $16.5 billion of transactional experience) who specializes in structured finance and financial engineering. Additionally, Richard is a PhD candidate at the University of Oklahoma, where his quantitative research focuses on medical diagnostic and treatment disparities in Native American and minority communities.  

Joining Richard at the helm is our Chief Technology Officer, Jeremy Lasman, a brilliant innovator with a track record of harnessing cutting-edge technologies for social good. As a former SpaceX technologist and pioneer in quantum computing applications, Jeremy brings unparalleled technical expertise to our team. However, what sets him apart is his unwavering commitment to leveraging his skills to benefit humanity. Growing up in an underserved community, Jeremy intimately understands the urgency of bridging the digital divide and democratizing access to lifesaving innovations.

Our clinical team is led by Dr. Allan Tissenbaum, a renowned physician-scientist with over 30 years of experience serving diverse patient populations. He has assembled a team of clinicians, researchers, and community health workers who reflect the rich diversity of our target communities. This includes individuals from racial and ethnic minorities, LGBTQ+ backgrounds, and people with disabilities, who bring invaluable lived experience and cultural competence to our work.

We have established robust partnerships with grassroots organizations, patient advocacy groups, and local health systems in our regions to ensure our solution is genuinely community-driven. These collaborations are not mere token gestures; they are the lifeblood of our design and implementation process. 

Our commitment to community engagement extends beyond the design phase. As we deploy our solution in underserved settings, we work with local partners to provide training, support, and resources that empower healthcare providers and patients. 

Our measure of success is not only the accuracy of our algorithms but by the tangible improvements in health outcomes for the communities we serve. We are not just building a product; we are building a movement for health equity. With every misdiagnosis prevented and every life saved, we are one step closer to realizing our vision of a world where every patient, regardless of background, receives the care they need and deserve. 

We have selected the prototype stage for DiagnosisAid based on our early progress in developing our quantum AI-powered diagnostic tool, and the construction of the prototype has begun. We expect to have our prototype operationalized by the time the MIT Solve cohort begins.

Over the past few weeks, our team has laid the groundwork for the core technology components of DiagnosisAid. We have conducted extensive research on the latest advancements in quantum computing and have begun experimenting with integrating these techniques with our medical AI algorithms.

At this stage, we have developed a basic proof-of-concept demonstrating the feasibility of using quantum algorithms to process large volumes of medical data and generate rapid diagnostic insights. While this is still a rudimentary prototype, it has shown promising results in our initial internal testing.

On the user interface front, we have created initial sketches and wireframes that illustrate our vision for how physicians and patients will interact with the platform. These designs are still early and require further refinement based on user feedback.

We have also started engaging with potential clinical partners to discuss the development and eventual testing of DiagnosisAid. We have had conversations with a Native American hospital and a handful of small hospitals in Idaho and have received positive interest in collaborating on this initiative. However, we have yet to formalize any partnerships or begin integrating our solution with their systems.

It is important to emphasize that we are still in the early stages of prototype development and are several months away from testing our solution with real users. Our current focus is on validating the core technical approach, refining our initial designs, and laying the groundwork for future clinical partnerships.

As we continue to develop DiagnosisAid, our next steps will be to:

1. Further refine our quantum algorithms and test them on larger medical datasets to assess their scalability and accuracy.

2. Build a functional prototype of the user interface that incorporates our initial designs and allows for fundamental user interactions.

3. Conduct early usability testing with a small group of healthcare providers to gather feedback on our approach and identify areas for improvement.

4. Formalize partnerships with one or two clinical sites to serve as pilot locations for the initial testing of DiagnosisAid with patients in real-time.

While we have not yet served any actual customers or beneficiaries, we believe our early progress demonstrates the potential of our approach and positions us well as we progress with the development of a fully functional prototype in the coming months.

We are excited about the potential impact of DiagnosisAid. We are committed to leveraging the power of quantum computing and AI to revolutionize access to rapid, accurate, and equitable medical diagnosis. As we continue to hit key milestones in our development process, we look forward to sharing further updates on our progress and the impact we are making.

At DiagnosisAid, we are guided by a bold vision to revolutionize global access to accurate, timely, and equitable medical diagnosis through quantum computing and AI. While we have made promising early progress in developing our prototype, we recognize that realizing the full potential of our solution will require overcoming significant barriers. The MIT Solve program offers a unique platform to help us navigate these challenges and accelerate our impact.

One of the critical barriers we face is access to the technical expertise and resources needed to scale our quantum computing capabilities. While we have demonstrated the feasibility of our approach on a small scale, we will need to substantially increase the power and efficiency of our algorithms to handle the massive volumes of medical data required for global deployment. We hope that through Solve, we can connect with leading experts in quantum computing and AI who can provide guidance and support in optimizing our technology for real-world impact.

Another significant challenge is navigating the complex regulatory and legal landscape surrounding the use of AI in healthcare. As a startup pioneering a novel approach to medical diagnosis, we must work closely with regulatory bodies to ensure that our solution meets the highest standards of safety, efficacy, and privacy. We believe the Solve network can help us connect with experienced legal and policy advisors who can guide us through this process and help us build trust with key stakeholders.

Equally important, we recognize that the success of DiagnosisAid will hinge on our ability to build strong partnerships with healthcare providers, payers, and patient communities worldwide. As a small team, we face challenges in establishing the credibility and reach needed to forge these relationships at scale. We see the Solve program as an invaluable platform to help us connect with a global network of healthcare leaders, innovators, and influencers who can open doors and help us drive the adoption of our solution in diverse settings.

Finally, as an early-stage startup, we face the constant challenge of securing the financial resources needed to sustain our growth and impact. We believe that Solve's focus on connecting innovators with a diverse ecosystem of supporters can help us identify aligned funding partners who share our vision for health equity. Beyond monetary support, we are excited about the potential for Solve to help us forge strategic partnerships, access new markets, and tap into a wealth of expertise and resources to accelerate our growth.

At its core, our decision to apply to Solve is driven by a deep alignment with the program's mission and values. The most pressing challenges of our time, such as the global burden of misdiagnosis, can only be solved through the collective efforts of diverse innovators, experts, and stakeholders. By joining the Solve community, we hope to contribute our unique perspective and innovative solution to this ecosystem while learning from and collaborating with others.

Our diagnostic tool makes previously unsolvable problems solvable and creates a healthier, more equitable world.

DiagnosisAid represents a groundbreaking approach to tackling the global challenge of medical misdiagnosis by harnessing the power of quantum computing and AI in a way that has never been done before. 

At the core of our innovation is the pioneering application of quantum computing to medical diagnosis. While AI has been used in healthcare for some time, integrating quantum algorithms represents a quantum leap forward regarding processing power, accuracy, and speed. By leveraging the unique properties of quantum systems, such as superposition and entanglement, we analyze vast amounts of medical data and generate diagnostic insights with unprecedented precision and efficiency.

This quantum advantage allows us to take a radically new approach to the diagnostic process. Rather than relying solely on human expertise or classical computational methods, DiagnosisAid combines the best of both worlds – the intuition and experience of clinicians with the unparalleled pattern recognition and predictive capabilities of quantum AI. This hybrid approach has the potential to unlock new frontiers in diagnostic accuracy, enabling earlier detection of rare and complex diseases and reducing the risk of harmful diagnostic errors.

Nevertheless, our innovation goes beyond just the technological breakthroughs. We are also pioneering a new model for developing and deploying AI in healthcare, prioritizing transparency, trust, and equity. We are committed to building our solution in close collaboration with the communities we serve, engaging patients, providers, and advocates as co-designers and co-owners of the technology. By democratizing access to cutting-edge diagnostic tools and ensuring that the benefits of innovation are shared equitably, we aim to shift power dynamics and promote a more inclusive and participatory approach to healthcare innovation.

 The potential impact of DiagnosisAid extends far beyond the immediate benefits to patients and providers. We can catalyze broader adoption of this transformative technology across the industry by demonstrating the feasibility and implications of quantum AI in healthcare. Our success could inspire other innovators to explore the applications of quantum computing in drug discovery, personalized medicine, and beyond, accelerating progress and unlocking new possibilities for human health and well-being.

Moreover, by reducing the burden of misdiagnosis on healthcare systems, DiagnosisAid could help to free up scarce resources and expertise to focus on other pressing challenges, such as expanding access to care, improving population health, and addressing the social determinants of health. Our solution can be a force multiplier for positive change, empowering healthcare leaders and policymakers to tackle systemic inequities and drive transformative impact at scale.

Ultimately, DiagnosisAid represents a new paradigm for approaching the challenge of diagnosis in healthcare. By combining cutting-edge technology with a deep commitment to social justice and community empowerment, we are poised to change the landscape of healthcare innovation and create a future where everyone can access the lifesaving power of accurate, timely, and personalized diagnosis. Our vision is not just to build a better diagnostic tool but to catalyze a movement for health equity and to inspire a new generation of innovators to tackle the world's most pressing challenges with courage, compassion, and creativity.

At DiagnosisAid, we have developed a clear theory of change that links our activities to immediate outputs and longer-term outcomes for our target population of underserved patients and healthcare providers. Our approach is grounded in a solid evidence base and a deep understanding of the complex factors contributing to the global misdiagnosis burden.

Our core activity is developing and deploying a quantum AI-powered diagnostic support tool that integrates seamlessly into clinical workflows. By leveraging the power of quantum computing and machine learning, our solution is designed to process vast amounts of patient data and generate highly accurate and personalized diagnostic insights in real-time. This technology is complemented by a user-friendly interface and intuitive visualizations that make it easy for clinicians to interpret and act on the information provided.

The immediate output of this activity is a significant improvement in the speed, accuracy, and consistency of diagnostic decision-making. By providing clinicians with rapid access to evidence-based insights and reducing the cognitive burden of complex cases, DiagnosisAid enables providers to make more informed and confident diagnoses at the point of care. This is supported by extensive research showing that AI-assisted diagnosis can improve diagnostic accuracy by up to 25% compared to unassisted clinicians, particularly in challenging cases such as rare diseases or atypical presentations (Topol, 2019; Liu et al., 2019).

In the short term, this improved diagnostic performance will translate into positive outcomes for patients and providers. For patients, the faster and more accurate diagnosis means earlier initiation of appropriate treatment, reducing the risk of complications and improving overall health outcomes. This is particularly important for conditions where early detection is critical, such as cancer or infectious diseases. 

Over the longer term, DiagnosisAid can drive transformative change in the healthcare landscape by reducing the systemic burden of misdiagnosis. Studies have shown that diagnostic errors contribute to over 100,000 deaths and $100 billion in wasted healthcare spending each year in the US alone (Singh et al., 2014). By preventing a significant portion of these errors, our solution could help to reduce preventable mortality, morbidity, and healthcare costs at a population level. This is supported by modeling studies suggesting that even a 5% reduction in diagnostic error rates could save thousands of lives and billions of dollars annually (Newman-Toker et al., 2019).

Critically, we believe that the impact of DiagnosisAid will be most pronounced among underserved and marginalized communities who currently bear the most significant burden of diagnostic inequity. Research has consistently shown that patients from racial and ethnic minorities, low-income backgrounds, and rural areas experience higher rates of misdiagnosis and diagnostic delay (Shen et al., 2019). By partnering with community health centers and safety-net providers to deploy our solution in these settings, we aim to narrow these disparities and ensure that the benefits of diagnostic innovation are shared equitably.

To support and amplify these outcomes, we are committed to a participatory approach that engages patients, providers, and community stakeholders as active partners in developing and evaluating our solution. 

At DiagnosisAid, our impact goals are centered around our mission to revolutionize global access to accurate, timely, and equitable medical diagnosis through the power of quantum AI. We have developed a set of specific, measurable, and time-bound goals that orient all aspects of our work and hold us accountable to the communities we serve.

Our primary impact goal is to reduce the global burden of misdiagnosis by 50% within the next ten years. This ambitious target is grounded in recognizing that diagnostic errors are a silent epidemic that affects millions of patients worldwide, with devastating consequences for individual and population health. 

We are tracking key performance indicators (KPIs) that capture our solution's reach, effectiveness, and equity to measure our progress towards this goal. These include:

1. Diagnostic Accuracy: We are measuring the percentage of cases where DiagnosisAid's top suggested diagnosis matches the final confirmed diagnosis compared to unassisted clinicians. We aim to achieve a 30% improvement in diagnostic accuracy within 2 years of deployment at Native American and urban hospitals that mainly serve people of color.

 2. Time to Diagnosis: We are tracking the average time from initial presentation to final diagnosis for patients who use DiagnosisAid, compared to standard care. Our goal is to reduce the time to diagnosis by 25% within the first year of deployment.

3. Patient Outcomes: We monitor a range of patient-centered outcomes, such as mortality rates, complication rates, and quality of life scores, for conditions where misdiagnosis is common. We aim to demonstrate a measurable improvement in these outcomes within five years of deployment.

4. Health Equity: We are measuring the adoption and impact of DiagnosisAid across diverse patient populations, focusing on underserved communities. We aim to ensure that at least 50% of our users come from low-income, minority, or rural backgrounds within three years of deployment.

5. Cost Savings: We are tracking the estimated healthcare costs avoided by preventing diagnostic errors and the associated complications. We aim to demonstrate a 10:1 return on investment for healthcare systems within five years of deployment.

We are leveraging various data sources and evaluation methods to collect these indicators. These include electronic health record data, claims data, patient-reported outcomes, and qualitative feedback from providers and patients. Academic institutions and research organizations will partner with us to conduct rigorous studies on the impact of our solution, including randomized controlled trials and health economic evaluations. We are also committed to transparency and accountability, regularly sharing our impact data with our stakeholders and the broader public.

Ultimately, our impact goals are not just numbers on a page – they represent our unwavering commitment to improving the lives of patients and providers worldwide. We aim to catalyze a global movement towards diagnostic excellence and health equity by setting bold targets and holding ourselves accountable to measurable results. We believe that by harnessing the power of innovation, collaboration, and data-driven decision-making, we can create a future where everyone can access the lifesaving power of accurate and timely diagnosis.

At the heart of DiagnosisAid is a revolutionary quantum AI platform combining cutting-edge advances in quantum computing, machine learning, and medical informatics to transform how we approach diagnostic decision-making.

The foundation of our technology is a custom-built quantum computing architecture that leverages the unique properties of quantum systems to perform complex computations at an unprecedented scale and speed. Unlike classical computers, which rely on binary bits that can only be in one state at a time (0 or 1), quantum computers use quantum bits or "qubits" that can exist in multiple states simultaneously through a phenomenon known as superposition. This allows quantum computers to perform certain types of calculations, such as optimization and simulation, exponentially faster than even the most influential classical supercomputers.

 Our team has developed proprietary algorithms that harness the power of quantum computing to process and analyze vast amounts of medical data in previously impossible ways. These algorithms are designed to identify complex patterns and relationships across multiple data modalities, including clinical notes, lab results, imaging studies, and genomic data. Leveraging techniques such as quantum annealing and quantum machine learning can generate highly accurate and personalized diagnostic insights.

We have curated one of the world's most extensive and diverse medical knowledge and patient information datasets to train our quantum AI models. This includes structured and unstructured data from electronic health records, clinical trials, scientific literature, expert consensus guidelines, and real-world evidence from millions of patient encounters across various geographic and demographic contexts.

Another key innovation of our technology is integrating quantum simulation and counterfactual reasoning into the diagnostic process. Using advanced quantum algorithms, we can generate and test millions of hypothetical patient scenarios in parallel, allowing us to explore the full range of potential diagnoses and treatment options for each case. This enables us to identify the most likely diagnosis based on the available evidence and the most effective and personalized management strategy for each patient.

To make this powerful technology accessible and usable for clinicians at the point of care, we have developed an intuitive and user-friendly interface that seamlessly integrates with existing clinical workflows and electronic health record systems. Our platform uses natural language processing and voice recognition to allow clinicians to input patient data and receive diagnostic recommendations in real-time without disrupting their everyday clinical routines. 

Importantly, we have designed our quantum AI platform with a strong emphasis on safety, security, and ethical considerations. We have implemented rigorous data governance and privacy protection measures to ensure that patient information is always kept confidential and secure. We have also developed a robust framework for algorithmic transparency and accountability, including regular audits and validation studies to assess the performance and fairness of our models across different patient populations.

Ultimately, our core technology represents a paradigm shift in approaching medical diagnosis and decision-making. Our vision is to create a future where every patient, regardless of background or location, can benefit from the most advanced and effective diagnostic tools powered by cutting-edge quantum and AI technology.

Management: 3; two FT, one PT

Technical Development: 5 FT

One year

As an African American man, CEO, and co-founder, Richard has dealt with inequities working on Wall Street, and as a social entrepreneur. This is why Richard is keenly focused on democratizing medical diagnostics, technology, and financial access. DiagnosisAid is made up of 75% people of color, and 25% women. The ratio of women to men will improve as we move to the next phase and begin testing our prototype. As we build out the Board of Directors, the composition will include 50% members from lesser developed countries, and at least 50% women overall. Our mission is global, and the BOD involvement will reflect this. We do not refer to our company diversity as DEI, we refer to it as “good business.”

At DiagnosisAid, our business model is designed to create value for our key stakeholders: patients, providers, and payers – by delivering a transformative diagnostic support tool that improves patient outcomes, reduces healthcare costs, and advances health equity.

Our primary customers are healthcare providers, including physicians, nurses, and other clinicians responsible for making diagnostic decisions in various settings, from primary care clinics to emergency departments to specialty referral centers. We offer these providers access to our cutting-edge quantum AI platform through a software-as-a-service (SaaS) model, where they can input patient data and receive real-time diagnostic recommendations and decision support at the point of care.

We differentiate our offering through the unparalleled accuracy, speed, and personalization of our diagnostic insights, powered by our proprietary quantum algorithms and vast medical knowledge base. By providing clinicians with a powerful tool to augment their expertise and intuition, we enable them to make faster, more confident, and more evidence-based diagnostic decisions to improve patient outcomes and satisfaction.

We offer a compelling value proposition for healthcare payers, including insurance companies, government programs, and self-insured employers, by reducing the costs and complications associated with misdiagnosis and diagnostic delay. Our platform can generate significant cost savings and quality improvements across the healthcare system by preventing unnecessary tests, procedures, and hospitalizations and ensuring patients receive the proper treatment at the right time. We work with payers to develop customized pricing and reimbursement models that align with their specific needs and priorities, such as population health management, risk stratification, and value-based care. Our model will also fully integrate with major medical recordkeeping systems.

Significantly, we recognize that our ultimate beneficiaries are the patients who rely on accurate and timely diagnosis to receive the care they need. Our main goal is to provide world-class diagnoses to people who live in communities where doctors and medical staff may be average or below average. To ensure that our platform reaches the populations who stand to benefit the most, we have developed a tiered pricing model that adjusts our fees based on the socioeconomic status and disease burden of the communities served by each healthcare provider. We also partner with community health centers, safety-net hospitals, and global health organizations to provide subsidized or pro bono access to our platform.

To generate revenue, we plan to charge healthcare providers a subscription fee for access to our platform based on the volume and complexity of the diagnostic cases they process. We'll offer premium features and customization options for an additional fee, such as integration with electronic health record systems, advanced analytics and reporting, and clinical decision support for specific disease areas. Data report sales to researchers and corporations will be another source of revenue.

As we scale our business, we are committed to reinvesting a significant portion of our operating income into ongoing R&D. A percentage of profits will support global health initiatives and health equity programs, aligning with our mission to democratize access to diagnostic excellence worldwide.

DiagnosisAid has a clear plan for achieving financial sustainability through revenue streams, strategic partnerships, and impact investing, even though we are in the early stages of developing our innovative quantum AI diagnostic support platform.

Our primary revenue source will be subscription fees from healthcare providers using our platform. We are developing a competitive and tiered pricing model to serve a range of customers, from individual practices to large health systems. To validate our value proposition and pricing, we seek pilot partners to launch at least one paid pilot within 6-12 months.

Simultaneously, we are exploring strategic partnerships with healthcare and life sciences stakeholders to apply our quantum AI technology in drug discovery, clinical trial recruitment, and precision medicine. We aim to establish at least one strategic partnership within 12-18 months, potentially providing significant funding for development and commercialization.

To support our early-stage growth, we seek seed funding of $1-2 million from venture capital firms, angel investors, and strategic partners within the next 9-12 months. This will allow us to expand our core team, refine our technology, and establish initial customer and partner relationships.

As a mission-driven company, we are interested in innovative financing mechanisms like pay-for-success arrangements, where we receive upfront funding to deploy our platform in underserved communities and are paid based on achieved outcomes in reducing diagnostic errors and improving patient outcomes. As part of our long-term sustainability strategy, we plan to explore this with potential impact investing partners. 

We will build a lean and agile organization to maximize our limited resources, leveraging in-house expertise and outsourced partners to scale our technology infrastructure. We will prioritize rapid experimentation and iteration to refine our product and business model based on real-world feedback and data.

Despite the challenges ahead, our innovative approach and commitment to impact position us well for long-term success. By focusing on our mission, leveraging our unique capabilities, and building solid relationships with customers, partners, and investors, we are confident in building a financially sustainable and impactful business that advances medical diagnosis and improves patient lives worldwide.